Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study

References

• Sachdev P. The current status of tardive dyskinesia. Australian and New Zealand Journal of Psychiatry 2000; 34: 355–369
   PubMed Web of Science ®Google Scholar
• Crane G E. Pseudoparkinsonism and tardive dyskinesia. Archives of Neurology 1972; 27: 426–430
   PubMedGoogle Scholar
• Kane J M, Woerner M, Borenstein M. Integrating incidence and prevalence of tardive dyskinesia. Psychopharmacology Bulletin 1986; 22: 254–258
   PubMedGoogle Scholar
• Saltz B L, Woerner M G, Kane JM, et al. Prospective study of tardive dyskinesia incidence in the elderly. Journal of the American Medical Association 1991; 266: 2402–2406
   PubMed Web of Science ®Google Scholar
• Woerner M G, Alvir J M, Saltz B L, Lieberman J A, Kane J M. Prospective study of tardive dyskinesia in the elderly: rates and risk factors. American Journal of Psychiatry 1998; 155: 1521–1528
   PubMed Web of Science ®Google Scholar
• Jus A, Pineau R, Lachance R, et al. Epidemiology of tardive dyskinesia, part, I.I. Diseases of the Nervous System 1976; 37: 210–214
   PubMedGoogle Scholar
• Chouinard G, Annable L, Ross-Chouinard A, Nestoros J N. Factors related to tardive dyskinesia. American Journal of Psychiatry 1979; 136: 79–82
   PubMed Web of Science ®Google Scholar
• DeVeaugh-Geiss J. Prediction and prevention of tardive dyskinesia. Tardive dyskinesia and related involuntary movement disorders, J DeVeaugh-Geiss. John Wright, Bristol 1982; 161–178
   Google Scholar
• Barnes TRE, Braude W M. Persistent akathisia associated with early tardive dyskinesia. Postgraduate Medical Journal 1984; 60: 51–53
   PubMed Web of Science ®Google Scholar
• Goswami U, Channabasavanna S M. Is akathisia a forerunner of tardive dyskinesia?. Clinical Neurology and Neurosurgery 1984; 86: 107–110
   PubMedGoogle Scholar
• Sachdev P, Kruk J. Clinical characteristics and predisposing factors in acute drug-induced akathisia. Archives of General Psychiatry 1994; 51: 963–974
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology: publication ADM 76–338, W Guy. Department of Health, Education, and Welfare, Washington, DC 1976
   Google Scholar
• Simpson G M, Angus J W. A rating scale for extrapyramidal side effects. Acta Psychiatrica Scandinavica 1970; 212(Suppl.)11–19
   Google Scholar
• Sachdev P. A rating scale for drug-induced akathisia: development, reliability and validity. Biological Psychiatry 1994; 35: 263–271
   PubMedGoogle Scholar
• Overall J E, Gorham D R. The Brief Psychiatric Rating Scale. Psychological Reports 1962; 10: 799–812
   Web of Science ®Google Scholar
• Schooler N R, Kane J M. Research diagnoses for tardive dyskinesia. Archives of General Psychiatry 1982; 39: 486–487
   PubMed Web of Science ®Google Scholar
• Sachdev P. Acute and tardive drug-induced akathisia. Drug-induced movement disorders, K D Sethi. Macel Dekker, New York 2003; 129–164
   Google Scholar
• Jeste D V, Rosenblatt J E, Wagner R L, Wyatt R J. High serum neuroleptic levels in tardive dyskinesia?. New England Journal of Medicine 1979; 301: 1184
   PubMed Web of Science ®Google Scholar
• Yassa R, Nair V, Schwartz G. Tardive dyskinesia and the primary psychiatric diagnosis. Psychosomatics 1984; 25: 135–138
   PubMed Web of Science ®Google Scholar
• Kapitany T, Meszaros K, Lenzinger E, et al. Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophrenia Research 1998; 32: 101–106
   PubMed Web of Science ®Google Scholar
• Muscettola G, Barbato G, Pampallona S, Casiello M, Bollini P. Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors and association with tardive dyskinesia. Journal of Clinical Psychopharmacology 1999; 19: 203–208
   PubMed Web of Science ®Google Scholar
• Brown K W, White T, Wardlow J M, Walker N, Foley D. Caudate nucleus morphology in tardive dyskinesia. British Journal of Psychiatry 1996; 169: 631–636
   PubMedGoogle Scholar
• Chakos M H, Lieberman J A, Bilder R M, et al. Increase in caudate nuclei volumes of first-episode schizophrenic patients taking anti-psychotic drugs. American Journal of Psychiatry 1994; 151: s1430–s1436
   PubMed Web of Science ®Google Scholar
• Davis J M. Comparative doses and costs of antipsychotic medication. Archives of General Psychiatry 1976; 33: 858–861
   PubMed Web of Science ®Google Scholar